Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Relapse and / or Refractory Myeloma”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)Ended earlyNCT05117008
What this trial is testing

Maintenance Belantamab Mafodotin (Blenrep®) After B-cell Maturation Antigen-Directed Chimeric Antigen Receptor T-cell Therapy in Patients With Relapsed and/or Refractory Multiple Myeloma

Who this might be right for
Refractory Multiple MyelomaRelapse Multiple Myeloma
Medical College of Wisconsin 1
Early research (Phase 1)Not Yet RecruitingNCT07735546
What this trial is testing

UB-VV500 With Rapamycin in Relapsed/Refractory Multiple Myeloma

Who this might be right for
Multiple Myeloma in RelapseMultiple Myeloma (MM)
Umoja Biopharma 100
Testing effectiveness (Phase 2)Study completedNCT01058434
What this trial is testing

Safety and Efficacy of TKI258 in Relapsed or Refractory Multiple Myeloma Patients, Who Are With or Without t(4;14) Chromosomal Translocation

Who this might be right for
Relapsed or Refractory Multiple Myeloma
Novartis Pharmaceuticals 43
Early research (Phase 1)Looking for participantsNCT07003555
What this trial is testing

Dual-target BCMA-CD19 CAR-T Cell Therapy for RR/MM With Extramedullary Infiltration

Who this might be right for
Relapsed or Refractory Multiple Myeloma (RRMM)
Beijing GoBroad Hospital 18
Testing effectiveness (Phase 2)Study completedNCT02185820
What this trial is testing

Phase I/II Study of Carfilzomib, Pomalidomide and Dexamethasone in Relapsed And/Or Refractory Multiple Myeloma Patients (CPD)

Who this might be right for
Multiple Myeloma
European Myeloma Network B.V. 57
Early research (Phase 1)Study completedNCT00560391
What this trial is testing

Dasatinib in Combination With Revlimid (and Dexamethasone)

Who this might be right for
Multiple Myeloma
Bristol-Myers Squibb 35
Early research (Phase 1)Study completedNCT02431208
What this trial is testing

Atezolizumab (Anti-Programmed Death-Ligand 1 [PD-L1] Antibody) Alone or in Combination With an Immunomodulatory Drug and/or Daratumumab in Participants With Multiple Myeloma (MM)

Who this might be right for
Multiple Myeloma
Hoffmann-La Roche 85
Testing effectiveness (Phase 2)Ended earlyNCT02188368
What this trial is testing

Pomalidomide for Lenalidomide for Relapsed or Refractory Multiple Myeloma Patients

Who this might be right for
Multiple Myeloma
Oncotherapeutics 45
Not applicableStudy completedNCT00569868
What this trial is testing

UARK 2005-05, Coagulation-Related Effects of Velcade Treatment in Patients With Relapsed or Refractory Multiple Myeloma

Who this might be right for
MULTIPLE MYELOMA
University of Arkansas 11
Early research (Phase 1)Active Not RecruitingNCT05391750
What this trial is testing

Venetoclax and Tocilizumab for the Treatment of Patients With Relapsed or Refractory t(11;14) Multiple Myeloma

Who this might be right for
Recurrent Plasma Cell MyelomaRefractory Plasma Cell Myeloma
Emory University 7
Testing effectiveness (Phase 2)Looking for participantsNCT06066346
What this trial is testing

Talquetamab for People With Multiple Myeloma Who Have Received BCMA CAR T-Cell Therapy

Who this might be right for
Multiple Myeloma
Memorial Sloan Kettering Cancer Center 17
Testing effectiveness (Phase 2)Looking for participantsNCT03761108
What this trial is testing

Phase 1/2 Study of Linvoseltamab in Adult Patients With Relapsed or Refractory Multiple Myeloma

Who this might be right for
Multiple Myeloma
Regeneron Pharmaceuticals 387
Testing effectiveness (Phase 2)Study completedNCT03215524
What this trial is testing

Daratumumab, Low-Dose Oral Dexamethasone and Cyclophosphamide With Or Without Pomalidomide

Who this might be right for
Multiple Myeloma
Canadian Myeloma Research Group 120
Early research (Phase 1)Active Not RecruitingNCT06604715
What this trial is testing

JNJ-87562761 in Participants With Relapsed or Refractory Multiple Myeloma

Who this might be right for
Relapsed or Refractory Multiple Myeloma
Janssen Research & Development, LLC 17
Testing effectiveness (Phase 2)Ended earlyNCT01979276
What this trial is testing

Study of Pomalidomide, Dexamethasone, and Romidepsin for Rel/Ref Myeloma

Who this might be right for
Multiple Myeloma
Weill Medical College of Cornell University 4
Testing effectiveness (Phase 2)Ended earlyNCT01484626
What this trial is testing

Bendamustine, Wkly Bortezomib, Lenalidomide and Dexamethasone for Multiple Myeloma

Who this might be right for
Multiple Myeloma
Loyola University 3
Early research (Phase 1)Ended earlyNCT00560352
What this trial is testing

Safety Study of Dasatinib With Bortezomib (Velcade®) and Dexamethasone for Multiple Myeloma

Who this might be right for
Multiple Myeloma
Bristol-Myers Squibb 16
Early research (Phase 1)Ended earlyNCT00004058
What this trial is testing

12-O-Tetradecanoylphorbol-13-acetate in Treating Patients With Hematologic Cancer or Bone Marrow Disorder

Who this might be right for
Chronic Myeloproliferative DisordersLeukemiaLymphoma+4 more
University of Medicine and Dentistry of New Jersey
Early research (Phase 1)Study completedNCT01344876
What this trial is testing

Phase I Study of OPB-51602 in Patients With Hematologic Malignancies

Who this might be right for
Multiple MyelomaNon-Hodgkin LymphomaAcute Myeloid Leukemia+2 more
Otsuka Pharmaceutical Co., Ltd. 20
Early research (Phase 1)Study completedNCT04674813
What this trial is testing

CC-95266 in Participants With Relapsed and/or Refractory Multiple Myeloma

Who this might be right for
Multiple Myeloma
Juno Therapeutics, a Subsidiary of Celgene 130
Next Page